期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 326, 期 -, 页码 19-27出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2018.11.002
关键词
Multiple sclerosis; Interferon-beta; Luciferase-based bioassay; Bridging ELISA; Anti-drug antibodies; Neutralizing antibodies
资金
- Innovative Medicines Initiative Joint Undertaking [115303]
- European Union
- EFPIA Companies
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-beta) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-beta-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-beta ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据